Lifecore to Provide CDMO Services for Nirsum’s Clinical Development of Opioid Use Disorder Treatment

• Lifecore Biomedical will provide CDMO services to Nirsum Laboratories for the clinical development of NRS-033, a treatment for opioid and alcohol use disorders.

• The partnership includes technology transfer and assessment of the fill and finish process, leveraging Lifecore’s expertise in sterile injectables.

Lifecore Biomedical, Inc. has announced a new agreement with Nirsum Laboratories, Inc. to support the clinical development of Nirsum’s lead candidate, NRS-033. The collaboration will focus on fill and finish technology transfer, a key component in the development and commercialisation of sterile injectable pharmaceutical products.

NRS-033, owned and developed by Nirsum, is an innovative treatment for opioid use disorder (OUD) and alcohol use disorder (AUD). The therapy is now entering Phase 2 clinical trials, and the agreement will see Lifecore supplying filled syringes for use in these studies.

Paul Josephs, CEO of Lifecore, expressed enthusiasm for the partnership: “With growing concerns about opioid and alcohol addiction in the U.S. and beyond, we’re grateful for the opportunity to support Nirsum on this important and promising treatment.” He highlighted Lifecore’s expertise in complex formulations as critical to advancing the fill and finish process for NRS-033.

Nirsum’s CEO, Dr. Nikej Shah, emphasised the unmet need for innovative treatments in addiction medicine: “We believe NRS-033 will be a key innovation, solving the critical problem of short therapeutic retention of available therapies that results in high relapse rates.” Shah added that the collaboration with Lifecore marks a significant step in bringing this novel treatment closer to commercialisation.